2005 US Science Budget May Mean Belt Tightening

A post-election "lame duck" Congress recently returned to Washington, DC, and approved an omnibus funding measure for fiscal year 2005, which began October 1.

Written byTed Agres
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A post-election "lame duck" Congress recently returned to Washington, DC, and approved an omnibus funding measure for fiscal year 2005, which began October 1. By holding overall discretionary domestic spending to last year's levels, the measure gives Spartan increases, and even some cuts, to scientific and medical research.

The $388.4 billion omnibus appropriations bill (HR 4818) approved on November 20 combines the remaining nine of 13 spending measures that had not been passed before Congress adjourned in October. The measure consolidates budgets for the National Institutes of Health, the National Science Foundation, and most federal agencies other than the Pentagon and Department of Homeland Security.

Under the compromise legislation, NIH will receive about $28.4 billion, a 2% increase of $563 million over last year. This will give most institutes and centers increases of 1.6% to 2.4%, failing to keep pace with the biomedical research and development price index, projected at ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies